Deep Lens, Inc., a Columbus, OH-based AI-driven digital pathology company focused on clinical trial recruitment at the time of diagnosis, closed a $14m Series A financing.
The round led by Northpond Ventures, with participation from existing investors Rev1 Ventures, Sierra Ventures, and Tamarind-Hill Partners.
The company, which has raised $17.5m in total funding, will use the funding to further expand its artificial intelligence (AI) and platform product development activities and scale its service, sales, and marketing organizations.
Co-founded by CEO Dave Billiter, chief scientist TJ Bowen, Ph.D.,, and president Simon Arkell, Deep Lens has develped technology called VIPER (Virtual Imaging for Pathology Education and Research), which combines artificial intelligence (AI) with advanced pathology workflows to facilitate peer-to-peer collaboration and patient identification for clinical trials.
By identifying eligible patients at the time of their diagnosis, VIPER can help fast-track trial enrollment and potentially shorten the duration of the trial.